Cardiff Lexington Corporation
CDIX operates in the healthcare facilities and services industry, focusing on biotechnology, and generates revenue primarily through its services and products in this sector.
Business. CDIX.PK is a healthcare company operating within the Healthcare Facilities & Services industry, with a primary focus on biotechnology activities. The firm generates revenue through service-based models typical of the healthcare services sector. Specific details regarding its operating segments, headquarters location, and primary stock exchange listings are not available in the provided data. Consequently, the company is described at the industry level without further geographic or segmental breakdown.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
CDIX.PK is a healthcare company operating within the Healthcare Facilities & Services industry, with a primary focus on biotechnology activities. The firm generates revenue through service-based models typical of the healthcare services sector. Specific details regarding its operating segments, headquarters location, and primary stock exchange listings are not available in the provided data. Consequently, the company is described at the industry level without further geographic or segmental breakdown.
CDIX has a capital structure marked by a high debt-to-equity ratio of 6.08, indicating a significant reliance on debt financing. The company's liquidity is assessed as medium, with a current ratio of 0.87, suggesting that it may struggle to meet short-term obligations with its current assets. The company's free cash flow is negative at -$6.82 million, reflecting a cash outflow that could impact its ability to fund operations or invest in growth.
In terms of profitability, CDIX reported a net loss of $5.51 million, with a return on equity of -1.79 and a return on assets of -0.19, both significantly below the industry median. These metrics indicate that the company is not generating returns that meet the expectations of its equity and asset base. The operating income of $1.10 million is modest compared to the gross profit of $7.21 million, suggesting that operating expenses are a significant drag on profitability.
The company's revenue is concentrated in a single segment, as disclosed in its financials, with no geographic diversification provided in the available data. This lack of diversification could expose the company to higher risks if the primary market or product line experiences a downturn.
Looking at the growth trajectory, CDIX has reported a revenue of $11.54 million, but the company's net loss and negative cash flows suggest a challenging path to growth. The outlook for the current fiscal year does not indicate a significant improvement in revenue or profitability, with the company likely to continue facing financial pressures.
The risk assessment highlights a medium liquidity risk and a low dilution risk. The company's net cash is negative after subtracting total debt, which could limit its financial flexibility. However, the dilution risk is low, indicating that the company is not expected to issue additional shares in the near term.
Recent events, as reflected in the financial data, show a continued financial strain with a net loss and negative cash flows. The company's financial health is a concern, and it may need to take corrective actions to improve its financial position.
- CDIX has a high debt-to-equity ratio of 6.08, indicating a significant reliance on debt financing.
- The company reported a net loss of $5.51 million, with a return on equity of -1.79 and a return on assets of -0.19, both significantly below the industry median.
- The company's revenue is concentrated in a single segment, with no geographic diversification provided in the available data.
- The company's liquidity is assessed as medium, with a current ratio of 0.87, suggesting potential difficulties in meeting short-term obligations.
- The company's free cash flow is negative at -$6.82 million, reflecting a cash outflow that could impact its ability to fund operations or invest in growth.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- Return On Assetsnet_income / total_assets
- CDIX.PK Market data — financials · 2026-05-27
Ownership & reference
Insider activity
Short positioning
Geographic breakdown
Intel & risk
Evidence & claims
From filings & derived data- Return on equity (FY 2025-12-31): 223.0%Derived (calculated)
- Net income (YoY) (2025-12-31 vs 2024-12-31): -66.7%Derived (calculated)
- Return on assets (FY 2025-12-31): -18.9%Derived (calculated)
- Current ratio (FY 2025-12-31): 0.87xDerived (calculated)
- Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): -192.0%Derived (calculated)
- Debt-to-equity (FY 2025-12-31): -10.53xDerived (calculated)
- Operating income (YoY) (2025-12-31 vs 2024-12-31): 668.8%Derived (calculated)
- Revenue (YoY) (2025-12-31 vs 2024-12-31): 39.5%Derived (calculated)
- Total liabilities (YoY) (2025-12-31 vs 2024-12-31): 59.4%Derived (calculated)
- Net margin (FY 2025-12-31): -47.7%Derived (calculated)
- Long-term debt (YoY) (2025-12-31 vs 2024-12-31): 101.5%Derived (calculated)
- Cost of revenue (YoY) (2025-12-31 vs 2024-12-31): 12.7%Derived (calculated)
- Gross margin (FY 2025-12-31): 62.5%Derived (calculated)
- Gross profit (YoY) (2025-12-31 vs 2024-12-31): 62.7%Derived (calculated)
- Total assets (YoY) (2025-12-31 vs 2024-12-31): 21.6%Derived (calculated)
- Current liabilities (annual): USD 25.83MSEC XBRL filing
- Shares outstanding (annual): 13.7MSEC XBRL filing
- Shareholders' equity (annual): USD -2.47MSEC XBRL filing
- Revenue (annual): USD 11.54MSEC XBRL filing
- Pre-tax income (annual): USD -5.75MSEC XBRL filing
- Net income (annual): USD -5.51MSEC XBRL filing
- Long-term debt (annual): USD 18.56MSEC XBRL filing
- Total operating expenses (annual): USD 6.11MSEC XBRL filing
- Cost of revenue (annual): USD 4.33MSEC XBRL filing